IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still’s disease

• Published in: Annals of the rheumatic diseases Vol. 69; no. 2; pp. 466 - 467
• Main Authors: Naumann, L, Feist, E, Natusch, A, Langen, S, Krause, A, Buttgereit, F, Burmester, G-R
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group Ltd and European League Against Rheumatism 01.02.2010; BMJ Publishing Group; BMJ Publishing Group LTD
• Subjects: Adult; Aged; Antirheumatic Agents - therapeutic use; Biological and medical sciences; Clinical trials; Disease; Diseases of the osteoarticular system; Drug Therapy, Combination; Female; Gangrene; Humans; Immunomodulators; Inflammatory joint diseases; Interleukin 1 Receptor Antagonist Protein - therapeutic use; Male; Medical sciences; Middle Aged; Neutrophils; Patients; Pharmacology. Drug treatments; Receptors, Interleukin-1 - antagonists & inhibitors; Still's Disease, Adult-Onset - drug therapy; Treatment Outcome; Tumor necrosis factor-TNF; Human; Immunomodulator; Refractory; Still disease; Treatment; Diseases of the osteoarticular system; Rheumatology; Adult; Antagonist; Anakinra
• ISSN: 0003-4967; 1468-2060
• DOI: 10.1136/ard.2009.108068

ADM, adalimumab; ALT, alanine aminotransferase (normal value <34); AST, aspartate aminotransferase (normal value <35); CRP, C-reactive protein (normal value <0.5); CYP, cyclophosphamide; CyA, ciclosporin A; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; ETN, etanercept; IFL, infliximab; LFM, leflunomide; MTX, methotrexate; TNF, tumour necrosis factor.